Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTA-EB-TATE in Metastatic Oncocytic (Hurthle-Cell) Thyroid Cancer
NCT06991738Phase 2Not yet recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Nov 2026
- Primary completion
- Jul 2032
- Countries
- 1
01
Overview
A Phase 2 trial of EBTATE in Oncocytic Thyroid Carcinoma, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
EBTATE
03
Conditions
Oncocytic Thyroid Carcinoma
Beyond the preview
Go deeper on NCT06991738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06991738.